All In Biotech

Drug Trial Radar · NCT04759534

Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia

Phase III Clinical Study to Evaluate the Efficacy and Safety of PCSK9 Inhibitors in the Prevention of Chinese Heterozygous Familial Hypercholesterolemia

Last checked: Nov 19, 2026Latest source record: Aug 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

20

Actual

Start

Sep 10, 2020

Primary completion

Oct 30, 2021

Study completion Nov 30, 2021

Sponsor

Lead sponsor
Shenzhen People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Innovent Biopharmaceutical Co., Ltd.
First posted
Feb 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study plans to enroll several patients with heterozygous familial hypercholesterolemia, randomly assigned to different dose groups, and randomly receiving subcutaneous injection of IBI306150 mg or placebo every two weeks: or subcutaneous injection of IBI306 450mg every four weeks (n=49) or placebo (n=25) treatment, treatment lasted for 12 weeks. During randomization, the LDL-C level (\<4.8mmol/L or ≥4.8mmol/L) observed during the screening period visit (VI), and whether ezetimibe was used for stratification. After 12 weeks, each group entered the 12-week open-period treatment, in which subjects in the IBI306 group continued to receive IBI306 treatment, and subjects in the placebo group stopped using placebo and received IBI306 treatment. The exploratory endpoint is the population pharmacokinetic characteristics of IBI306 in Chinese heterozygous familial hypercholesterolemia population.

Conditions

  • Efficacy and Safety
  • Heterozygous Familial Hypercholesterolemia
  • PCSK9

Interventions

  • protein convertase subtilisin/kexin type 9 inhibitorBiological

    IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. LDL-CTime frame: 12 weeks after baseline
  2. LDL-CTime frame: 24 weeks after baseline
  3. non HDL-CTime frame: 12 weeks after baseline
  4. non HDL-CTime frame: 24 weeks after baseline
  5. ApoBTime frame: 12 weeks after baseline
  6. ApoBTime frame: 24 weeks after baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • xili People's Hospital

    Shenzhen, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.